Vaxxinity, Inc. is a biotechnology company. The Company’s synthetic peptide vaccine platform (Vaxxine Platform) enables a new class of therapeutics that seeks to improve access to treatments for a range of indications. Its pipeline consists of five chronic disease product candidates from early to late-stage development across multiple therapeutic areas, including Alzheimer’s Disease (AD), Parkinson’s Disease (PD), migraine and hypercholesterolemia. Its UB-311 targets toxic forms of aggregated amyloid-b (Ab) in the brain to fight AD. Its UB-312 targets toxic forms of aggregated a-synuclein in the brain to fight PD and other synucleinopathies, such as Lewy body dementia (LBD) and multiple system atrophy (MSA). Its UB-313 targets Calcitonin Gene-Related Peptide (CGRP) to fight migraines. Its Anti-PCSK9 targets proprotein convertase subtilisin/kexin type 9 serine protease (PCSK9) to lower low-density lipoprotein (LDL) cholesterol and reduce the risk of cardiac events.